B-Cell Navigator is a dual-engine platform for rapid, scalable discovery of target-specific antibodies at single-B-cell resolution, from the full immune repertoire

MR. Guimarães [1], M. Lisetto [1], A. C. Trigo [1], A. I. Soares [1], O. Fomochova [1], I. Silva [1], J. Canossa [1], S. Lemos [1] I. Toth [1], J. Queiroz [1] and T. P. Resende [1]

>1,000-fold multiparameter optimisation of an enzyme inhibitor to generate a best-in-class antibody. First human dosed within 18 months of programme initiation. Now in Phase 3.

It combines naive, semi-synthetic, immune, and named libraries with phage, mammalian, yeast, and single B-cell platforms in one customisable workflow, so the route to a candidate follows your biology rather than a single platform. Developability is built in from the start through patent-protected mammalian display, not patched after a failed lead. The fact sheet sets out the libraries, platforms, formats, and tough-target applications behind any target, any format.

Many cancer drivers are intracellular, beyond conventional antibodies, but HLA class I displays their fragments as peptide-HLA complexes. The challenge is discriminating a mutant pHLA from its wild-type form, often one amino acid apart, since any cross-reactive clone becomes on-target toxicity. FairJourney Bio used counter-selection across four naïve human libraries to recover 53 mutant-specific Fvs and a lead T-cell engager at 2.97 nM.

Why antibody programmes stall in redesign loops, and how integrating discovery and engineering gets from hit to optimized lead in under 12 months. With Maria Pajuelo, FairJourney Bio.